Back

Optimizing foundational therapies in HF ‒ can we do better?

23 May 2022 (17:52 - 18:00)
Organised by:
Congress Presentation Part of: SGLT2 inhibition across the spectrum of heart failure: maximizing patient benefits in clinical practice Chronic Heart Failure Open Access Heart Failure 2022

About the speaker

Photo
Professor Andrew Stewart Coats

Heart Research Institute, Sydney (Australia)

5 More presentations in this session

Presentation thumbnail
Welcome and introduction.
Professor S. Anker (Berlin, DE)
Slides Video
Presentation thumbnail
SGLT2 inhibition ‒ early, first-line therapy across the spectrum of HF.
Doctor D. Tomasoni (Brescia, IT)
Slides Video
Presentation thumbnail
SGLT2 inhibition in patients with HFpEF ‒ a case-based discussion.
Professor G. Rosano (London, GB)
Slides Video
Presentation thumbnail
Interactive panel discussion.
Professor S. Anker (Berlin, DE) Professor A. Stewart Coats (Sydney, AU) Professor G. Rosano (London, GB) Doctor D. Tomasoni (Brescia, IT)
Video
Presentation thumbnail
Conclusion.
Professor C. Lam (Singapore, SG)
Video

Access the full session

Session thumbnail
SGLT2 inhibition across the spectrum of heart failure: maximizing patient benefits in clinical practice
Video

The Event

Event poster

Heart Failure 2022

23 May 2022 17:52 CET
You may be interested in
thumbnail
Congress Session
Bridging gaps in heart failure care: primary care trends, exercise, kidney function, and global health perspectives
thumbnail
Congress Session
Nursing and Allied Professions Investigator Award
thumbnail
Congress Session
Which device might help your HFpEF patient?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources